Real World Longer-Term Follow-Up Data Confirms the Effectiveness and Safety of Avelumab 1st Line Maintenance Treatment of Low-Burden Urothelial Cancer

Results from the AVENANCE trial suggest that avelumab may provide a promising maintenance treatment option for patients with low-burden urothelial carcinoma, showing encouraging survival and progression-free survival outcomes after chemotherapy.